Detalles de la búsqueda
1.
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
Clin Immunol
; 225: 108679, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33485895
2.
Initial safety analysis of a randomized phase II trial of nelipepimut-Sâ¯+â¯GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
Clin Immunol
; 201: 48-54, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30817999
3.
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.
Clin Cancer Res
; 26(11): 2515-2523, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32071118
4.
Nucleic acid molecular biomarkers for diagnostic biodosimetry applications: use of the fluorogenic 5'-nuclease polymerase chain reaction assay.
Mil Med
; 167(2 Suppl): 16-9, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11873502
5.
The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis.
Cancer Res
; 73(9): 2817-28, 2013 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23610451
6.
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
J Immunol
; 177(1): 84-91, 2006 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16785502
Resultados
1 -
6
de 6
1
Próxima >
>>